Study of ALXN2030 for antibody-mediated rejection after kidney transplant
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial tests a new drug called ALXN2030 for people who have a type of rejection called antibody-mediated rejection (AMR) after a kidney transplant. It aims to see if the drug can help treat this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a kidney transplant at least 6 months ago.
- You have active or ongoing antibody-mediated rejection (AMR) confirmed by a kidney biopsy.
- You have certain antibodies or signs of rejection in your blood or biopsy.
- Your kidney function (eGFR) is at least 30 mL/min/1.73 m2.
- You need to have received vaccines for meningococcal infection, pneumonia, and sometimes Hib before starting the study.
- You weigh at least 110 pounds (50 kg) at screening.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called SG301 to see if it can safely treat antibody-mediated rejection (a type of kidney rejection) in people who have had a kidney transplant. It may help stop the immune system from attacking the transplanted kidney.
This study tests an experimental drug called CID-103 to treat antibody-mediated rejection (ABMR), a type of immune response that damages transplanted kidneys. The drug targets immune cells that attack the transplant, and researchers hope it may help preserve kidney function and prevent transplant failure.
This trial tests a new two-step treatment for a type of long-term kidney rejection (chronic active antibody-mediated rejection) in transplant recipients. First, you receive an infusion of CD38 antibodies to clear harmful cells, then a months-long course of azathioprine pills to maintain the benefit and protect your kidney.
This Phase 2 study looks at whether blood test “biomarkers” can guide safely changing anti-rejection medicines after an ABO-compatible kidney transplant. It may help some people reduce certain medicines while keeping the new kidney protected from rejection.
This trial tests a new drug called ALXN1920 for adults with primary membranous nephropathy (PMN), a kidney disease where the immune system attacks the kidneys. It is for people at high risk of their disease getting worse, and it compares the new drug added to standard care versus standard care alone.
This study tests a new treatment called BiTE (a type of immunotherapy that helps your immune cells attack harmful antibodies) for people whose transplanted kidney is being damaged by chronic active antibody-mediated rejection. The goal is to see if it can safely slow or stop this damage.
Hear when a new Antibody-mediated Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.